Myeloma Trial, Recruiting NCT05970198 Sponsor: Fuling Zhou Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT05970198
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with multiple myeloma and are receiving initial treatment to prepare for a stem cell transplant using your own stem cells
  • You are willing and able to follow all birth control requirements during the trial
  • You are generally able to carry out daily activities with little or no limitation (confirm with trial site)
  • Your liver function blood test results are within an acceptable range (confirm with trial site)
  • Enough of your stem cells (a specific type called CD34+ cells) have already been successfully collected for transplant
  • Your blood counts, including infection-fighting cells and platelets, are at an acceptable level (confirm with trial site)
  • Your doctor expects you to live for more than 3 months
  • You (or a close family member) have signed a form giving your informed consent to take part

Who may not be able to join:

  • Your doctor does not think you would be able to tolerate certain treatments used in this trial, specifically a drug called melphalan or radiation therapy
  • You have a known active hepatitis B or hepatitis C infection, or have tested positive for HIV
  • You have heart or blood vessel disease that is severe or not well controlled
  • You have a serious physical or mental health condition that your doctor feels would make it unsafe or unsuitable for you to participate

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fuling Zhou, Wuhan University

Phone: +86-02767813137

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fuling Zhou
Registry
ClinicalTrials.gov
Start date
14 June 2023
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate and above 100 days after transplantation (≥ CR rate)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov